Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€1.86

€1.86

2.200%
0.04
2.200%
-

-

 
08:20 / Tradegate WKN: A41GYL / Name: Mindwalk Holdings Corp. / Stock / ? /

Mindwalk Holdings Corp. Stock

There is an upward development for Mindwalk Holdings Corp. compared to yesterday, with an increase of €0.040 (2.200%).

Pros and Cons of Mindwalk Holdings Corp. in the next few years

Pros
?
M***** P*******
?
B****
?
S********** s********
Cons
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'

News

MindWalk Applies HYFT® to Detect Functional Adjacency Risk in AI-Designed Therapeutics
MindWalk Applies HYFT® to Detect Functional Adjacency Risk in AI-Designed Therapeutics

AUSTIN, Texas – MindWalk Holdings Corp. (NASDAQ:HYFT) (“MindWalk” or the “Company”), a Bio-Native AI therapeutic research and technology company, today announced an application of its

MindWalk Validates Platform Precision with Breakthrough Discovery Targeting Pathogenic TDP-43 in Neurodegenerative Disease
MindWalk Validates Platform Precision with Breakthrough Discovery Targeting Pathogenic TDP-43 in Neurodegenerative Disease

14 January 2026 – VICTORIA, British Columbia – MindWalk Holdings Corp. (“MindWalk” or the “Company”) (Nasdaq: HYFT) today announced the discovery and validation of monoclonal antibodies and

MindWalk Advances Universal Influenza Program with a Breakthrough Functional Insight
MindWalk Advances Universal Influenza Program with a Breakthrough Functional Insight

Validated Across Influenza A and Influenza B, Including H3N2 Subclade K and Zoonotic Influenza A Subtypes H5, H7, H9

 

AUSTIN, Texas – January 9th, 2026 - MindWalk Holdings Corp.